Is there more than C-reactive protein and fibrinogen?

The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease


      Incidence of atherosclerosis and atherosclerosis-related complications will increase significantly in the coming decennia. Research identified many serum and plasma markers that are associated with cardiovascular disease. However, little is known about the prognostic value of these markers to identify patients at risk for future cardiovascular events. Therefore, we aimed to investigate the prognostic value of three of these markers (soluble CD40 ligand (sCD40L), interleukin-6 (IL-6) and oxidized low-density lipoprotein (oxLDL)) with respect to coronary vascular disease and stroke. For this reason the Medline database was searched for the period January 1999–January 2005. To be selected in our study, concentration of the marker had to be determined at baseline, follow-up period had to be longer than 3 months and an estimate of relative risk had to be available. Based on these criteria, 4 studies for sCD40L, 10 for IL-6 and 2 for oxLDL were selected. Relative risk estimates adjusted for potential confounders varied between 1.9 and 2.8 for sCD40L, between 1.1 and 3.1 for IL-6 and between 1.9 and 3.2 for oxLDL. In conclusion, this systematic review shows that sCD40L, IL-6 and oxLDL are associated with an increased relative risk of developing cardiovascular disease.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ross R.
        Atherosclerosis: an inflammatory disease.
        N Eng J Med. 1999; 340: 115-126
        • Ridker P.M.
        • Buring J.E.
        • Shih J.
        • Matias M.
        • Hennekens C.H.
        Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.
        Circulation. 1998; 98: 731-733
        • Yarnell J.W.G.
        • Patterson C.C.
        • Sweetnam P.M.
        • Lowe G.D.O.
        Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies.
        Eur Heart J. 2004; 25: 1049-1056
        • Ernst E.
        • Resch K.L.
        Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.
        Ann Intern Med. 1993; 118: 956-963
        • Danesh J.
        • Collins R.
        • Appleby P.
        • Peto R.
        Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease.
        JAMA. 1998; 279: 1477-1482
        • Danesh J.
        • Phil D.
        • Wheeler J.G.
        • et al.
        C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
        N Eng J Med. 2004; 350: 1387-1397
        • Mach F.
        • Schönbeck U.
        • Sukhova G.K.
        • et al.
        Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signalling in atherosclerosis.
        Proc Natl Acad Sci USA. 1997; 94: 1931-1936
        • Lutgens E.
        • Daemen M.J.
        CD40-CD40L interactions in atherosclerosis.
        Trends Cardiovasc Med. 2002; 12: 27-32
        • Lutgens E.
        • Cleutjens K.B.
        • Heeneman S.
        • et al.
        Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
        Proc Natl Acad Sci USA. 2000; 97: 7464-7469
        • Aukrust P.
        • Müller F.
        • Ueland T.
        • et al.
        Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.
        Circulation. 2001; 100: 614-620
        • Biasucci L.M.
        • Vitelli A.
        • Liuzzo G.
        • et al.
        Elevated levels of interleukin-6 in unstable angina.
        Circulation. 1996; 94: 874-877
        • Rifai N.
        • Joubran R.
        • Yu H.
        • Asmi M.
        • Jouma M.
        Inflammatory markers in men with angiographically documented coronary heart disease.
        Clin Chem. 1999; 45: 1967-1973
        • Maier W.
        • Altwegg L.A.
        • Corti R.
        • et al.
        Inflammatory markers at the site of ruptured plaque in acute myocardial infarction. Locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein.
        Circulation. 2005; 111: 1355-1361
        • Schieffer B.
        • Selle T.
        • Hilfiker A.
        • et al.
        Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis.
        Circulation. 2004; 110: 3493-3500
        • Ehara S.
        • Ueda M.
        • Naruko T.
        • et al.
        Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes.
        Circulation. 2001; 103: 1955-1960
        • Toshima S.
        • Hasegawa A.
        • Kurabayashi M.
        • et al.
        Circulation oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease.
        Arterioscler Thromb Vasc Biol. 2000; 20: 2243-2247
        • Weinbrenner T.
        • Cladellas M.
        • Covas M.I.
        • et al.
        High oxidative stress in patients with stable coronary heart disease.
        Atherosclerosis. 2003; 168: 99-106
        • Schönbeck U.
        • Varo N.
        • Libby P.
        • Buring J.
        • Ridker P.M.
        Soluble CD40 ligand and cardiovascular risk in women.
        Circulation. 2001; 104: 2266-2268
        • Baldus S.
        • Heeschen C.
        • Meinertz T.
        • et al.
        Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.
        Circulation. 2003; 108: 1440-1445
        • Varo N.
        • de Lemos J.A.
        • Libby P.
        • et al.
        Soluble CD40L: risk prediction after acute coronary syndromes.
        Circulation. 2003; 108: 1049-1052
        • Heeschen C.
        • Dimmeler S.
        • Hamm C.W.
        • et al.
        Soluble CD40 ligand in acute coronary syndromes.
        N Engl J Med. 2003; 348: 1104-1111
        • Kinlay S.
        • Schwartz G.G.
        • Olsson A.G.
        • et al.
        Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
        Circulation. 2004; 110: 386-391
        • Heeschen C.
        • Dimmeler S.
        • Hamm C.W.
        • et al.
        Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes.
        J Am Coll Cardiol. 2005; 45: 229-237
        • Harris T.B.
        • Ferrucci L.
        • Tracy R.P.
        • et al.
        Associations of elevated interleukin-6 and C-reactive protein levels with mortality in elderly.
        Am J Med. 1999; 106: 506-512
        • Ridker P.M.
        • Rifai N.
        • Stampfer M.J.
        • Hennekens C.H.
        Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.
        Circulation. 2000; 101: 1767-1772
        • Ridker P.M.
        • Hennekens C.H.
        • Buring J.E.
        • Rifai N.
        C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
        N Engl J Med. 2000; 342: 836-843
        • Koukkunen H.
        • Penttila K.
        • Kempainnen A.
        • et al.
        C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris.
        Ann Med. 2001; 33: 37-47
        • Lindmark E.
        • Diderholm E.
        • Wallentin L.
        • Siegbahn A.
        Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or non-invasive strategy.
        JAMA. 2001; 286: 2107-2113
        • Volpato S.
        • Guralnik J.M.
        • Ferrucci L.
        • et al.
        Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study.
        Circulation. 2001; 103: 947-953
        • Pradhan A.D.
        • Manson J.E.
        • Rossouw J.E.
        • et al.
        Inflammatory biomarkers, hormon ereplacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.
        JAMA. 2002; 288: 980-987
        • Luc G.
        • Bard J.M.
        • Juhan-Vague I.
        • et al.
        C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study.
        Arterioscler Thromb Vasc Biol. 2003; 23: 1255-1261
        • Conway D.S.G.
        • Buggins P.
        • Hughes E.
        Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation.
        Am Heart J. 2004; 148: 462-466
        • Doo Y.C.
        • Han S.J.
        • Lee J.H.
        • et al.
        Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris.
        Am J Cardiol. 2004; 93: 554-558
        • Pai J.K.
        • Pischon T.
        • Ma J.
        • et al.
        Inflammatory markers and the risk of coronary heart disease in men and women.
        N Engl J Med. 2004; 351: 2599-2610
        • Holvoet P.
        • Harris T.B.
        • Tracy R.P.
        • et al.
        Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly. Findings from the Health, Aging and Body Composition Study.
        Arterioscler Thromb Vasc Biol. 2003; 23: 1444-1448
        • Shimada K.
        • Mokuno H.
        • Matsunaga E.
        • et al.
        Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease.
        Atherosclerosis. 2004; 174: 343-347
        • Holvoet P.
        • Kritchevsky S.B.
        • Tracy R.P.
        • et al.
        The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging and body composition cohort.
        Diabetes. 2004; 53: 1068-1073